About this trial
This study aims to evaluate the tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery in the patients with gastric cancer who received proximal gastrectomy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Aged older than 18 years and younger than 85 years
Primary gastric adenocarcinoma confirmed by preoperative pathology result
cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition
Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision
Disqualifiers
Negative preoperative biopsy
Too late tumour stage or metastasis (cT4b/M1)
BMI>30 kg/m2
previous neoadjuvant chemotherapy or radiotherapy
Trial population
Patients undergoing proximal gastrectomy with D2 lymphadenectomy plus complete mesogastric excision. At the same time, the patients met the above inclusion and exclusion criteria.
Trial design
Other
Prospective
Treatments tested in this trial
In addition to routine diagnosis and treatment, no additional intervention measures were taken.
Other interventionThis study does not impose any intervention on the patients
Treatment groups
Trial outcomes
Primary outcomes
Rate of tumor deposit at the fusion site of the right gastric mesentery and left gastric mesentery; Through postoperative pathological diagnosis
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Jichao Qin
Lead sponsor
First Affiliated Hospital of Zhejiang University
Sponsor institution